Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by Notch pathway activation to be selected for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

25770.2 PFLS-LS

Project title

Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by Notch pathway activation to be selected for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.

Texts for this project

	German	French	Italian	English
Short description		-	-
Abstract		-	-

Inserted texts

Category	Text
Short description (German)	Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by Notch pathway activation to be selected for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.
Short description (English)
Abstract (German)	Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by NOTCH pathway activation, for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.
Abstract (English)